دورية أكاديمية
Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
| العنوان: | Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults. |
|---|---|
| المؤلفون: | Eiden J; FluGen, Inc, Madison, Wisconsin, USA., Fierro C; Johnson County Clin-Trials, Lenexa, Kansas, USA., Schwartz H; Research Centers of America, Hollywood, Florida, USA., Adams M; Alliance for Multispecialty Research, Lexington, Kentucky, USA., Ellis KJ; Alliance for Multispecialty Research, Norfolk, Virginia, USA., Aitchison R; North Rim Consulting, Longmont, Colorado, USA., Herber R; FluGen, Inc, Madison, Wisconsin, USA., Hatta Y; FluGen, Inc, Madison, Wisconsin, USA., Marshall D; FluGen, Inc, Madison, Wisconsin, USA., Moser MJ; FluGen, Inc, Madison, Wisconsin, USA., Belshe R; Saint Louis University, St Louis, Missouri, USA., Greenberg H; Stanford University, Stanford, California, USA., Coelingh K; St Helena, California, USA., Kawaoka Y; Influenza Research Institute, University of Wisconsin, Madison, Wisconsin, USA., Neumann G; Influenza Research Institute, University of Wisconsin, Madison, Wisconsin, USA., Bilsel P; FluGen, Inc, Madison, Wisconsin, USA. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2022 Dec 28; Vol. 227 (1), pp. 103-112. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Influenza Vaccines* , Influenza, Human*, Humans ; Adult ; Influenza A Virus, H3N2 Subtype ; Antibodies, Viral ; Vaccination ; Hemagglutination Inhibition Tests |
| مستخلص: | Background: We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection. Methods: Serosusceptible subjects aged 18-49 years were randomized to receive 2 doses (108-109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines. Results: The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%-56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%-92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%-85.8%) of recipients. Mucosal and cellular immune responses were also induced. Conclusions: These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza. Clinical Trials Registration: NCT03999554. Competing Interests: Potential conflicts of interest. J. E. is a consultant to FluGen. R. B., H. G., and K. C. serve on FluGen's Clinical Advisory Board. Y. K. and G. N. are founders of FluGen. R. H., Y. H., D. M., M. M., and P. B. are employees of FluGen. All other authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| References: | Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. (PMID: 21306569) Vaccine. 2018 Aug 9;36(33):5097-5103. (PMID: 30007825) Vaccine. 2017 Jul 24;35(33):4177-4183. (PMID: 28668565) J Clin Microbiol. 1986 Jul;24(1):157-60. (PMID: 3722363) Vaccine. 2009 Aug 6;27(36):4953-60. (PMID: 19540952) Viral Immunol. 2002;15(2):295-323. (PMID: 12081014) Lancet Infect Dis. 2012 Jan;12(1):36-44. (PMID: 22032844) J Hyg (Lond). 1972 Dec;70(4):767-77. (PMID: 4509641) Vaccine. 2016 Sep 30;34(42):5090-5098. (PMID: 27595896) Clin Infect Dis. 2019 Oct 30;69(10):1817-1823. (PMID: 31102401) Nat Med. 2012 Jan 29;18(2):274-80. (PMID: 22286307) Influenza Other Respir Viruses. 2019 Sep;13(5):429-437. (PMID: 31225704) Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578. (PMID: 28933664) J Infect Dis. 2000 Mar;181(3):1133-7. (PMID: 10720541) Vaccines (Basel). 2021 Nov 24;9(12):. (PMID: 34960134) PLoS One. 2008 Jul 02;3(7):e2574. (PMID: 18596908) Antimicrob Agents Chemother. 2007 Nov;51(11):4001-8. (PMID: 17724151) J Infect Dis. 2022 Aug 12;226(1):83-90. (PMID: 34323977) Vaccine. 1999 Dec 10;18(9-10):899-906. (PMID: 10580204) |
| فهرسة مساهمة: | Keywords: H3N2; drift; influenza; intranasal; live; mucosal; vaccine Local Abstract: [plain-language-summary] In recent years, influenza A H3N2 viruses have evolved into multiple cocirculating clades, resulting in low vaccine efficacy and highlighting the need for more effective influenza vaccines. In a previous challenge study, a single intranasal dose of the investigational vaccine M2SR demonstrated protection against a highly drifted H3N2 influenza challenge virus in a subset of vaccine recipients with a signature immune response. Increasing the dose of the M2SR vaccine in this phase1b study demonstrated a statistically significant increase in the proportion of subjects with the signature immune responses seen previously. The vaccine-induced antibodies were cross-reactive with a panel of drifted H3N2 viruses from 2007 to 2019. Additionally, M2SR generated a rise in serum hemagglutination inhibition antibody titer in 71% of subjects. In contrast, the H3N2 seroresponse rate for the licensed intranasal vaccine FluMist is 10% in seronegative adults. Moreover, M2SR elicited mucosal and cell-mediated immune responses. This study demonstrates that the intranasal M2SR generates a multifaceted immune response and has the potential to provide better efficacy against vaccine-matched strains and influenza drift variants reducing the need to update the vaccine on an annual basis. This is a noteworthy step in the development of a broadly protective influenza vaccine. |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03999554 |
| المشرفين على المادة: | 0 (Influenza Vaccines) 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20221109 Date Completed: 20221230 Latest Revision: 20230118 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9796169 |
| DOI: | 10.1093/infdis/jiac433 |
| PMID: | 36350017 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiac433 |